In view of the studies reported by us and others that PARP-1 inhibition protects against not only eosinophilic inflammation but also against lung neutrophilia by blocking activation of NF-κB (pro-inflammatory transcription factor), the chances of success of these compounds in treatment/prevention of severe form of asthma and/or COPD would be high (Figure 3 depicts potential model). This evidence concerns the gene PARP1 and chronic obstructive pulmonary disease.